OrthogenRx markets GenVisc 850 and TriVisc biologic products. OrthogenRx executes at a level of efficiency that allows them to invest in pricing programs.
The company has completed recruitment and treated all patients in its Phase III study with the viscosupplement, JTA-004, in patients with knee osteoarthritis.
The orthopedic industry faced unique challenges and profound uncertainty in 2020. We recap market’s recovery through nine months and our 2020 projections.
With its renewed focus on winning market share, Medtronic estimates Mazor X placements outpaced Globus Medical’s ExcelsiusGPS by a factor of 1.5 in 3Q20.